Pandemic & Infectious Disease — 2026-05-08

Active Outbreak Tracker

Hantavirus (Andes Virus) — Global / Cruise Ship

• Status: Active international alert; 3 confirmed deaths; 20+ countries under monitoring
• Key Development: An outbreak of Andes virus — a rare, rodent-borne strain of hantavirus capable of limited person-to-person transmission — erupted aboard a cruise ship in early April. By May 7, a Dutch flight attendant and a French national were among the latest individuals tested for exposure. Crucially, viral analysis conducted in South Africa showed no mutations in samples, offering some reassurance. Experts broadly agree the outbreak is serious but unlikely to become a pandemic, given Andes virus's biological limitations.
• Response: WHO held a public briefing on May 7 outlining containment efforts. Health authorities across four continents are actively tracing and monitoring passengers who disembarked before the outbreak was detected. WHO Director-General Tedros Adhanom Ghebreyesus used the moment to call for the U.S. to rejoin the agency, even as American officials continue cooperating operationally despite the formal withdrawal.

1 sources

nbcchicago.com

nbcchicago.com

WHO Pandemic Treaty Negotiations — Global

• Status: Stalled; no final agreement reached
• Key Development: Finalization of the WHO pandemic accord — intended to govern global responses to future disease outbreaks — has been delayed as talks on benefit-sharing of tests, vaccines, and biological samples broke down. The Guardian reported this week that countries are failing to agree on how to share outbreak-related resources, leaving the world in a precarious position ahead of any future pandemic.
• Response: Negotiators continue talks but no resolution timeline has been confirmed. Critics warn that without binding rules on information sharing and equitable vaccine access, the global community remains structurally unprepared for a repeat of a COVID-scale event.

Respiratory Virus Season — United States

• Status: Very Low activity; 2025–2026 season winding down
• Key Development: The CDC's respiratory illness surveillance network is reporting very low levels of COVID-19, influenza, and RSV activity nationally. The agency stated it does not anticipate producing additional seasonal outlook updates for the remainder of the 2025–2026 respiratory season, signaling an orderly close to this year's wave.
• Response: No new emergency measures are in place. Routine surveillance continues, with attention now shifting toward summer-season readiness and next-season vaccine formulation decisions.

Vaccine & Treatment Pipeline

• mRNA Flu Vaccine — mRNA-1010 (Moderna): A Phase 3 randomized controlled trial published in the New England Journal of Medicine this week found that Moderna's investigational mRNA-based seasonal influenza vaccine provided significantly better protection against influenza illness than standard-dose shots in adults aged 50 and older. The result marks a major milestone for mRNA platform expansion beyond COVID-19.

• Chikungunya Vaccine — IXCHIQ (Bavarian Nordic): The FDA this week approved Bavarian Nordic's chikungunya vaccine for individuals aged 12 and older. The approval is based on positive Phase 3 clinical trial results, providing an effective option for travelers and populations at risk of the mosquito-borne illness.

• VAX-31 Pneumococcal Vaccine (Vaxcyte): Vaxcyte announced this week that enrollment is now complete across all three of its Phase 3 trials — OPUS-1, OPUS-2, and OPUS-3 — evaluating VAX-31 for the prevention of invasive pneumococcal disease and pneumonia in adults. A total of 6,191 adults have been enrolled across the three studies. Topline safety and immunogenicity data from OPUS-1 are expected in Q4 2026.

• COVID & Shingles Vaccine Safety Data (HHS / CDC): KFF Health News reported this week that the Trump administration withdrew planned publication of two large federally-funded studies — combing millions of patient records — that found serious side effects from COVID-19 and shingles vaccines to be rare. HHS stated the authors "drew broad conclusions not supported by the underlying data." The suppression has drawn criticism from public health researchers.

Expert Analysis

Infectious disease experts moved quickly this week to contextualize the hantavirus cruise ship outbreak, with the dominant consensus being: alarming, but not a pandemic in the making. Writing in Forbes, ecologist John Drake argued that the biology of Andes virus inherently limits large-scale spread — the virus is not easily aerosolized for broad transmission and requires close contact with an infected individual or rodent reservoir. "The outbreak is serious," Drake noted, but pointed to fundamental virology as the key brake on runaway transmission.

NPR reported that multiple infectious disease specialists echoed this view, noting that Andes virus — while one of the few hantavirus strains capable of human-to-human spread — has never demonstrated the explosive, self-sustaining transmission chains that define pandemics. The outbreak aboard the cruise ship was characterized as a contained cluster amplified by the ship's close quarters, not evidence of a pathogen acquiring new capabilities. Health officials surveyed described the global risk as "limited."

Politically, WHO Director-General Tedros Adhanom Ghebreyesus leveraged the moment to publicly argue that the outbreak demonstrates why the United States should rejoin the WHO, calling the episode a case study in the value of international health coordination. Despite the formal U.S. withdrawal, American health officials have continued cooperating with WHO on outbreak response — a dynamic Tedros called constructive but insufficient for addressing future threats at scale.

Global Health Security

WHO Pandemic Treaty Impasse: The Guardian reported on May 5 that finalization of the WHO pandemic accord has stalled over disagreements on benefit-sharing — specifically, how pathogen samples, test kits, and vaccines developed from shared biological data should be distributed equitably to lower-income countries. Health security analysts warned that absent a binding framework, wealthier nations will again control access in any future outbreak.

U.S.–WHO Cooperation Despite Formal Withdrawal: Even as the United States remains formally outside the WHO, Politico reported this week that U.S. health officials are working alongside WHO on the hantavirus cruise ship response. The episode has reignited debate in Washington and Geneva about the consequences of the withdrawal for global health security infrastructure.

FDA Vaccine Study Suppression: The decision by HHS to block publication of two large government-funded studies showing rare serious side effects from COVID-19 and shingles vaccines raised concerns this week about the integrity of U.S. regulatory science. Researchers and public health advocates warned that suppressing favorable safety data could further erode vaccine confidence at a moment when the country faces active disease threats.

What to Watch Next

• Hantavirus outbreak trajectory: Whether health authorities successfully contain transmission among the hundreds of cruise ship passengers dispersed globally will be the defining test case of post-COVID outbreak response infrastructure. Any evidence of secondary clusters beyond the ship setting would significantly escalate the threat level.

• WHO pandemic treaty deadline: Negotiations are at a critical juncture. Watch for whether member states reach a breakthrough or formally announce another delay — the outcome will shape global epidemic preparedness frameworks for years to come, particularly around benefit-sharing and pathogen access rules.

• Moderna mRNA flu vaccine FDA review: With compelling Phase 3 data now published in the New England Journal of Medicine, the next milestone is an FDA submission and advisory committee review. An approved mRNA flu vaccine could transform seasonal influenza prevention, particularly for older adults.